Kenneth Galbraith, CEO Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Dawson James ups CollPlant PT to $15 from $9
Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...
Raymond James starts Cardiol Therapeutics at OP 2; PT $5
Raymond James launched coverage of Cardiol Therapeutics (TSX:CRDL) with an “outperform 2” rating and price target of $5 (Canadian). The stock closed $4 on Jan.23. Cardiol’s therapeutic strategy is focused around the...
Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported its 2019 i/Blue Imaging System development achievements and upcoming 2020 milestones. “2019 was a momentous year for the Company as...
AGP ups Itamar Medical PT to $19.50 from $15.50
Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $19.50 from $15.50, reflecting preliminary fourth quarter revenue results, 2020 guidance and a recent meeting with the company’s...
Ladenburg starts ArTara Therapeutics at buy; PT $45
Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...
Echelon starts Protech Home Medical at buy; PT $2.50
Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...
Genprex gets fast track designation for lung cancer gene therapy
The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...
Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial
Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. The trial will enroll some 120 patients to assess...
HCW lowers Capricor Therapeutics PT to $9
H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...
Just a few of the companies we’ve highlighted along the way
